TPI Reports First Quarter Fiscal Year 2013 Financial Results

15 Nov, 2012, 05:27 ET from Tianyin Pharmaceutical Co., Inc.

CHENGDU, China, Nov. 15, 2012 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for first quarter of the fiscal year 2013.

First Quarter Fiscal Year 2013 Ended September 30, 2012 Financial Highlights:

  • Revenue was $16.0 million compared with $17.5 million in 1Q12,
  • Operating income was $2.2 million, compared with $2.1 million in 1Q12,
  • Net Income was $1.5 million compared with $1.5 million in 1Q12,
  • Earnings per share of $0.05 per basic share, and $0.05 per diluted share, compared with $0.05 per basic share, or $0.05 per diluted share in 1Q12, 
  • Cash and cash equivalents totaled $37.5 million on September 30, 2012; Operating cash flow for the quarter ended September 30, 2012 was $0.5 million, compared with $3.6 million for the quarter ended September 30, 2011.   

Comparison of results for the quarters ended September 30, 2012 and 2011:

        Quarters            

Ended September 30,

2012

2011

 

(In millions)

Sales

$

16.0

$

17.5

Cost of sales

$

9.7

$

11.7

Gross profit

$

6.2

$

5.9

Total operating expenses

$

4.1

$

3.7

Provision for income taxes

$

0.6

$

2.1

Net income

$

1.5

$

1.5

Sales for the quarter ended September 30, 2012 was $16.0 million, a decrease of 8.6% as compared to $17.5 million for the quarter ended September 30, 2011. The sales decrease was predominately the result of continuous generic pricing pressure amid healthcare reform further augmented by continued restrictive government policies to prioritize the Essential Drug List (EDL) drug sales. This simultaneously reduced the sales of our higher margin generic pharmaceuticals. However, on a positive note we did observe a stabilization of the pricing trends from a year earlier while comparing the revenue for the quarter ended September 30, 2011 with the respective period in 2010.

Our top five product sales are: Gingko mihuan oral liquid (GMOL) for stroke and cardiovascular disorders: $6.3 million; Mycophenolate mofetil capsules (MM) for renal transplant: $1.8 million; Azithromycin tablets (AZI) for infection: $0.95 million; Qingre jiedu oral liquid (QR): $0.94 million and Qianlie Shule capsules (QS) for prostate conditions: $0.42 million. These products totaled $10.4 million in sales, representing 62% of the quarterly revenue. The previous two core products Apu Shuangxin Benorylate Granules (Apu) and Xuelian Chongcao (XLCC) which are not covered by EDL or National Reimbursement List (NRL), have not reached the level to be included in the top five products mainly caused by the healthcare reform regulations that favor EDL and NRL drugs. Compared with a year earlier, the total core product sales have risen significantly from the $5.6 million for the quarter ended September 30, 2011 mainly due to the significant rise of GMOL sales: a 117% growth from $2.9 million for the quarter ended September 30, 2011. The strong sale momentum in GMOL, in our opinion, is a result of the inclusion of GMOL in a number of Provincial EDL such as the provinces of Henan and Shandong and the City of Chongqing. We expect the trend to continue for the remainder of fiscal year 2013. 

Cost of Sales for the quarter ended September 30, 2012 was $9.7 million or 60.6% of sales, as compared to $11.7 million or 66.9% of sales for the quarter ended September 30, 2011. The percentage decrease in our cost of sales from the previous period was predominately attributable to a greater mix of higher margin products. While our market analysis has not yet fully affirmed a trend of continuous margin improvement we do believe that present sales data supports a flattening and slightly positive trend in our Cost of Sales. The contribution from our distribution business through Tianyin Medicine Trading (TMT) amounted to $3.9 million at 11% gross margin.

Gross Margin for the quarter ended September 30, 2012 was 39.1% as compared to 33.4% for the quarter ended September 30, 2011. As discussed above in the segment of costs of sales, our gross margin improved predominately as a result of a greater mix of higher margin products being sold during the period supported by a leveling off of negative pricing pressures in our lower margin generic portfolio. We expect that our overall gross margin in the near term, on a quarter to quarter comparison basis will likely improve from last year based upon continued improvement of our portfolio mix of higher margin products.

Operating Expenses were $4.1 million for the quarter ended September 30, 2012, as compared to $3.7 million for the quarter ended September 30, 2011. The increase in operating expenses was mainly associated with an increase in sales and marketing costs.

Net Income was $1.5 million with a net margin of 9.6% for the quarter ended September 30, 2012, as compared to net income of $1.5 million with net margin of 8.7% for the quarter ended September 30, 2011. This was predominately a direct result of improvements in our gross margins.

Diluted earnings per share for the quarter ended September 30, 2012 were $0.05 based on 29.3 million shares compared with the earnings of $0.05 per diluted share for the quarter ended September 30, 2011, based on 29.4 million shares.

Balance Sheet and Cash Flow

As of September 30, 2012, we had working capital totaling $44.2 million, including cash and cash equivalents of $37.5 million. Net cash generated in operating activities was $0.48 million for the three months ended September 30, 2012 as compared with net cash generated from operating activities as $3.6 million for the three months ended September 30, 2011. The net decrease in operating cash flow was predominately the result of; 1) an increase in the payment of trade notes payable of $3.1 million that was due this quarter, 2) a decrease of inventory of $1.4 million, and 3) an increase of advance from customer of $1.1 million. We believe that TPI is adequately funded to meet all of our working capital and capital expenditure needs for fiscal year 2013.

Business Development & Outlook

R&D for additional indications of flagship product Gingko Mihuan (GMOL)

Our flagship product Gingko Mihuan Oral Liquid (GMOL, SFDA certification number: H20013079; patent number: 20061007800225) contributes approximately 39% to our total revenue. Clinical application and information gathered from our physicians showed that in addition to our approved indication for GMOL: cardiovascular disorders, coronary heart disease and cerebral ischemic attack including strokes, off-label use of GMOL have been indicated in hepatic diseases and ophthalmological diseases. The validity of these observations is currently being investigated.

Jiangchuan Macrolide Project (JCM)

TPI has completed the 240-ton JCM facility for the R&D, manufacturing and sale of API and chemical intermediates of macrolide antibiotics. In January 2012, JCM was approved for its GMP certification designated as "CHUAN M0799," which is valid for the period of December 31, 2011 until December 31, 2015. The JCM underwent efficiency improvement and calibration for large scale production for the initial three months of operation. By July 2012, JCM has started producing macrolide API for TPI's production of Azithromycin Dispersible Tablets (SFDA No: H20074145).

Tianyin Medicine Trading Distribution Business (TMT)

TMT is established to distribute products manufactured by both TPI and other pharmaceutical companies to fuel our expanding sales network as well as to provide synergy to our existing organic product portfolio. TMT has been distributing mainly TPI's own products since its inception in 2009. Since 2010, TPI has signed and later extended distribution contracts with Jiangsu Lianshui Pharmaceutical ("Lianshui") to distribute Lianshui-branded generic injection products including cough suppressant, antibiotics, anti-inflammatory medicines and other healthcare indications. On average, TMT distribution revenue contributed approximately $3-5 million sales per quarter to our total revenue.

Pre-extraction and formulation plant development at Qionglai Facility (QLF)

In preparation for the new Good Manufacturing Practice (GMP) standards stipulated by the PRC government in early 2011, TPI initiated the process of optimizing the manufacturing facilities and production lines in compliance with the new GMP standards by 2013. Concurrently, the city of Chengdu has re-designated various industrial parks for particular industries such as automobile, biotechnologies, pharmaceuticals and chemical engineering. As a consequence, TPI's current manufacturing facility at the Longquan district, east of Chengdu, which is designated for use by the automotive industry, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for use by the pharmaceutical industry. The Qionglai facility (QLF) is approximately 18 miles from the Company's recently completed JCM facility. The proposed relocation project also includes our TCM pre-extraction plant, which is located near the center of city of Chengdu, a rapidly expanding residential area.

The QLF is estimated to be 80 mu or approximately 13 acres. Both pre-extraction plant and the formulation plant are to be relocated. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at TPI's facilities. The re-location and construction cost is estimated at $25 million for Phase I which, when completed in the end of calendar year 2012, will expand the current capacity by 30%. For Phase II of the QLF project, an additional $10 million in capital investment may be made to double the current capacity by calendar year 2013 if demand is required.

Fiscal Year 2013 Guidance

We are assuming that continued pricing pressures in our marketplace will remain constant for the upcoming year as we expect further reforms to be undertaken in the healthcare marketplace in China. This will continue to put pressure on our revenue growth in 2013, but we believe that JCM and TMT distribution business may help us overcome these external pressures and allow us to deliver 2013 revenue growth of approximately 10% to 15%. Therefore, we reiterate our fiscal 2013 revenue projection of approximately $75 to $80 million along with a net margin of approximately 10%.

We believe the following factors will influence the future growth perspectives of our Company: 1) Market expansion and revenue growth of TPI's core product portfolio led by flagship product Gingko Mihuan Oral Liquid (GMOL) and other major products; 2) Ramp up of JCM revenue in the fiscal year 2013; 3) The gradual stabilization of generic sales following the progressive pricing restrictions caused by the ongoing healthcare reform; 4) Steady TMT distribution revenue contribution; and 5) QLF relocation and smooth transition of production capacity. 

Management will continue to evaluate the Company's business outlook and communicate any changes on a quarterly basis or as when appropriate.

Conference Call

Senior management of TPI will host its earnings conference call for the first quarter fiscal year 2013 ending September 30, 2012 to be held at 8:30 a.m. ET on Thursday, November 15, 2012.

Interested parties may access the call by dialing 1-877-941-4774 (U.S.) or 1-480-629-9760 (International).

The conference ID is 4572569. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling 1-877-870-5176 (U.S.) or 1-858-384-5517

From:  11/15/2012 @ 11:30 am E.T. To:    11/29/2012 @ 11:59 pm E.T.

Replay Pin Number:  4572569

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=102266

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications.

For more information about TPI, please visit: http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

Investors Contact: ir@tpi.asia Web:   http://www.tianyinpharma.com Tel: +86-28-8551-6696 (Chengdu, China)        +86 134-36-550011 (China)

Address: 23rd Floor Unionsun Yangkuo Plaza No. 2, Block 3, South Renmin Road Chengdu, 610041 China

 

TIANYIN PHARMACEUTICAL CO., INC.

Consolidated Balance Sheets

September 30,

June 30,

2012

2012

Assets

(Unaudited)

Current assets:

Cash and cash equivalents

$

37,538,365

$

35,152,295

Restricted cash

1,583,000

3,534,550

Accounts receivable, net of allowance for doubtful accounts of $113,719

   and $113,862 at September 30, 2012 and June 30, 2012, respectively

10,264,113

11,272,367

Inventory

6,432,893

5,863,013

Advance payments

-

642,075

Other current assets

475,866

436,664

Total current assets

56,294,237

56,900,964

Property and equipment, net

26,040,538

26,458,349

Intangibles, net

20,732,243

20,958,226

Total assets

$

103,067,018

$

104,317,539

Liabilities

Current liabilities:

Accounts payable and accrued expenses

$

1,487,623

$

1,586,151

Accounts payable – construction related

410,899

740,832

Short-term bank loans

6,015,400

6,023,000

Trade notes payable

1,583,000

4,675,750

Advances from customer

1,139,760

-

Income tax payable

583,307

804,595

Other taxes payable

480,104

500,782

Other current liabilities

425,931

466,982

Total current liabilities

12,126,024

14,798,092

Total liabilities

12,126,024

14,798,092

Equity

Stockholders' equity:

Common stock, $0.001 par value, 50,000,000 shares authorized,

   29,332,791 shares issued and outstanding at September 30, 2012

   and June 30, 2012

29,446

29,446

Additional paid-in capital

30,117,997

30,104,902

Treasury stock

(135,925)

(135,925)

Statutory reserve

6,120,143

6,120,143

Retained earnings

46,563,946

45,022,329

Accumulated other comprehensive income

7,988,385

8,100,526

Total stockholders' equity

90,683,992

89,241,421

Noncontrolling interest

257,002

278,026

Total equity

90,940,994

89,519,447

Total liabilities and equity

$

103,067,018

$

104,317,539

 

 

TIANYIN PHARMACEUTICAL CO., INC.

Consolidated Statements of Operations and Comprehensive Income

(Unaudited)

For the Three Months Ended

September 30,

2012

2011

Sales

$

15,971,697

$

17,528,578

Cost of sales

9,727,993

11,675,529

Gross profit

6,243,704

5,853,049

Operating expenses

Selling expenses

2,761,438

2,477,326

General and administrative expenses

1,121,533

1,019,122

Research and development

215,930

210,715

Total operating expenses

4,098,901

3,707,163

Income from operations

2,144,803

2,145,886

Other income (expenses):

Interest income

67,602

34,961

Interest expense

(108,404)

(49,845)

Other income

-

(4,718)

Total other expenses

(40,802)

(19,602)

Income before provision for income taxes

2,104,001

2,126,284

Provision for income taxes

583,048

619,067

Net income

1,520,953

1,507,217

Less: net income attributable to noncontrolling interest

(20,664)

(18,023)

Net income attributable to Tianyin Pharmaceutical Co., Inc.

$

1,541,617

$

1,525,240

Basic earnings per share

$

0.05

$

0.05

Diluted earnings per share

$

0.05

$

0.05

Weighted average number of common shares outstanding:

Basic

29,332,791

29,396,276

Diluted

29,332,791

29,396,276

 

TIANYIN PHARMACEUTICAL CO., INC.

Consolidated Statements of Comprehensive Income

(Unaudited)

For the Three Months Ended

September 30,

2012

2011

Net income

$

1,520,953

$

1,507,217

Other comprehensive income (loss)

Foreign currency translation adjustment

(112,500)

947,507

Total other comprehensive income (loss)

(112,500)

947,507

Total Comprehensive income

1,408,453

2,454,724

Less: Comprehensive income (loss) attributable to the noncontrolling interest

(21,024)

237,404

Comprehensive income attributable to

Tianyin Pharmaceutical Co., Inc.

$

1,429,477

$

2,217,320

 

TIANYIN PHARMACEUTICAL CO., INC.

Consolidated Statements of Cash Flows

(Unaudited)

For the Three Months Ended

September 30,

2012

2011

Cash flows from operating activities:

Net Income

$

1,520,953

$

1,507,217

Adjustments to reconcile net income to net cash

provided by (used in) operating activities:

Depreciation and amortization

583,704

286,668

Share-based payments

13,095

Provision for bad debts

-

43,558

Changes in current assets and current liabilities:

Accounts receivable

993,591

699,626

Inventory

(577,022)

820,036

Advance payments

640,981

581,122

Other current assets

(39,736)

(63,523)

Accounts payable and accrued expenses

(96,477)

828,517

Accounts payable – construction related

(328,853)

(238,357)

Trade notes payable

(3,085,485)

-

Advances from customer

1,139,256

-

Income tax payable

(220,175)

(368,238)

Other taxes payable

(20,037)

(342,478)

Other current liabilities

(40,444)

(129,363)

Total adjustments

(1,037,602)

2,117,568

Net cash provided by operating activities

483,351

3,624,785

Cash flows from investing activities:

Addition to property and equipment

-

(113,819)

Additions to intangible assets – approved drugs

-

(765,282)

Additions to intangible assets – land use right

-

(1,815,804)

Net cash used in investing activities

-

(2,694,905)

Cash flows from financing activities:

Restricted cash

1,946,229

(1,530,564)

Proceeds from short-term bank loans

-

1,561,800

Net cash provided by financing activities

1,946,229

31,236

Effect of foreign currency translation on cash

(43,510)

621,270

Net increase in cash and cash equivalents

2,386,070

1,582,386

Cash and cash equivalents – beginning

35,152,295

31,724,906

Cash and cash equivalents – ending

$

37,538,365

$

33,307,292

Supplemental disclosures of cash activities

Cash paid for interest

$

108,404

$

49,845

Cash paid for income taxes

$

803,579

$

987,304

 

 

SOURCE Tianyin Pharmaceutical Co., Inc.



RELATED LINKS

http://www.tianyinpharma.com


http://public.viavid.com/index.php?id=102266


http://public.viavid.com/index.php?id=102266